Citations

Clear

9383 citation(s) found for "Thomas, PS".

P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
Ajufo, Helen, Harrison, Claire , Palmer, Jeanne , Derkach, Andrii, Roman‐Torres, Karisse, Buckley, Sarah , Rampal, Raajit K. , Bewersdorf, Jan Philipp , Palandri, Francesca , Mascarenhas, John , Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Дмитрович, Деркач Андрій

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e44640da

10.1097/01.hs9.0000971016.44640.da Get It

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
Delforge, Michel , Patel, Krina K. , Eliason, Laurie , Dhanda, Devender , Shi, Ling , Guo, Shien, Arnulf, Bertrand , Manier, Salomon , McKiver, Mihaela Popa, Marshall, Thomas, Cavo, Michèle , Nooka, Ajay K. , Callander, Natalie S. , Giralt, Sergio , Einsele, Hermann , Ailawadhi, Sikander , Cook, Mark , Rodríguez‐Otero, Paula

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e031009e

10.1097/01.hs9.0000970524.03100.9e Get It

P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Wang, Jacqueline , Tian, Zizhong , Qi, Xinyue , Jiang, Yi , Hampel, Paul J. , Leis, José F., Thanarajasingam, Gita , Inwards, David J. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Wang, Jacqueline F , Hwang, Steven R. , Zhang, Shijia, Godby, Richard , Parikh, Sameer A. , Ding, Wei , Muñoz, Javier , Paludo, Jonas , Kenderian, Saad S. , Muchtar, Eli , Tsang, Mazie , Hilal, Talal , Habermann, Thomas M. , Witzig, Thomas E. , Kay, Neil E. , Zhou, Shouhao , Wang, Yucai

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e47546cf

10.1097/01.hs9.0000969432.47546.cf Get It

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
Lim, Toon Wei , Camm, Alan John , Virdone, Saverio , Singer, Daniel E. , Bassand, Jean Pierre, Fonarow, Gregg C. , Ezekowitz, Michael D. , Kayani, Gloria , Kakkar, Ajay K. , Mahaffey, Kenneth W. , Pieper, Karen S. , Piccini, Jonathan P. , Investigators, for the GARFIELD‐AF and ORBIT‐AF, Piccini, Jonathan P , Fox, Keith A.A. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, for the GARFIELD‐AF and ORBIT‐AF

Mayo Clinic

Clinical Cardiology | August 21, 2023 | Volume: 46 | Issue: 11 | Pages: 1398-1407

10.1002/clc.24109 | PMID 37596725 Get It

AbstractBackgroundAn unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs).HypothesisAn externally validated model improves ICH risk stratification.MethodsIndependent factors associated with ICH were identified by Cox proportional hazard modeling, using pooled data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD‐Atrial Fibrillation) and ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registries. A predictive model was developed and validated by bootstrap sampling and by independent data from the Danish National Patient Register.ResultsIn the combined training data set, 284 of 53 878 anticoagulated patients had ICH over a 2‐year period (0.31 per 100 person‐years; 95% confidence interval [CI]: 0.28–0.35). Independent predictors of ICH included: older age, prior stroke or transient ischemic attack, concomitant antiplatelet (AP) use, and moderate‐to‐severe chronic kidney disease (CKD). Vitamin K antagonists (VKAs) were associated with a significantly higher risk of ICH compared with non‐VKA oral anticoagulants (NOACs) (adjusted hazard ratio: 1.61; 95% CI: 1.25–2.08; p = .0002). The ability of the model to discriminate individuals in the training set with and without ICH was fair (optimism‐corrected C‐statistic: 0.68; 95% CI: 0.65–0.71) and outperformed three previously published methods. Calibration between predicted and observed ICH probabilities was good in both training and validation data sets.ConclusionsAge, prior ischemic events, concomitant AP therapy, and CKD were important risk factors for ICH in anticoagulated AF patients. Moreover, ICH was more frequent in patients receiving VKA compared to NOAC. The new validated model is a step toward mitigating this potentially lethal complication.
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Steiner, Raphaël , Hwang, Steven R. , Khurana, Arushi , Annunzio, Kaitlin , Allen, Pamela B. , Baird, Katelin , Paulino, Darina, Alderuccio, Juan Pablo , Lossos, Izidore S. , David, Kevin A. , Evens, Andrew M. , Pandya, Karan, Bair, Steven M. , Kamdar, Manali , Aqeel, Sheeba Ba, Torka, Pallawi , Lynch, Ryan C. , Smith, Stephen D. , Noorani, Mansoor, Nair, Ranjit, Fang, Penny , Dabaja, Bouthaina S. , Lee, Hun Ju , Epperla, Narendranath , Allen, Pamela Blair , Baird, Katelin , Alderuccio, Juan Pablo , Lossos, Izidore S , David, Kevin , Evens, Andrew M , Kamdar, Manali , Torka, Pallawi , Smith, Stephen D , Ahmed, Sairah , Vega, Francisco , Lee, Hun Ju , Hwang, Steven R , Habermann, Thomas M. , Epperla, Narendranath , Feng, Lei , Ahmed, Sairah , Vega, Francisco , Wu, Susan Y. , Pinnix, Chelsea C. , Gunther, Jillian Rebecca

Mayo Clinic

Blood Advances | August 21, 2023 | Volume: 7 | Issue: 24 | Pages: 7485-7493

10.1182/bloodadvances.2023010700 | PMID 37603594 Get It

Abstract In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022. Treatment consisted of up to 1.2 mg/kg of BV and standard dose AVD IV on days 1 and 15 of each 28-day cycle for up to 6 cycles. At the time of treatment, the median patient age was 37 years, and a high-risk International Prognostic Score was observed in 46% of patients. Overall, 91% of patients received 6 cycles of AVD; 55% of patients did not receive the intended cumulative dose of BV (CDB); 28% of patients received two-thirds or less than the planned CDB. At a median follow-up time of 27.4 months (95% confidence interval [CI], 24.8-29), the median progression-free survival (PFS) was not reached, and the 12-month PFS was 90.3% (95% CI, 85.9-95.0). The impact of CDB on PFS was not significant (P = .15), nor was high CDB significantly associated with increased adverse events. In real-world experience, A + AVD is a highly effective treatment for patients with advanced-stage cHL, including for patients with prominent dose reductions of BV.
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Hsu, Chih–Yuan , Shah, Surbhi, Zon, Rebecca L. , Alsamarai, Susan, El-Bakouny, Ziad, Beeghly, Alicia, Doroshow, Deborah B. , Flora, Daniel , Fromowitz, Ariel, Jani, Chinmay , Khan, Hina, Klein, Elizabeth J. , Heater, Natalie Knox , Koshkin, Vadim S. , Kwon, Daniel H. , McKay, Rana R. , Nonato, Taylor K., Polimera, Hyma , Puc, Matthew , Shastri, Aditi , Singh, Sunny , Weissmann, Lisa B., Wilkins, Cy R. , Yoon, James J., Mishra, Sanjay , Grivas, Petros , Connors, Jean M. , Gandhi, Rikin, Gartrell, Benjamin A. , Makower, Della , Sullivan, Darciann O', Ohri, Nitin , Verma, Amit , Butt, Omar H. , Fiala, Mark A. , Monahan, Ryan, Bitran, Jacob D. , Hallmeyer, Sigrun , Mundt, Daniel , Pandravada, Sasirekha, Papaioannou, Philip V., Patel, Mauli, Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Bindal, Poorva , Lam, Barbara C.C., Piper‐Vallillo, Andrew J., Arvanitis, Panos , Vieira, Kendra, Angevine, Anne H., Bär, Michael, Prete, Salvatore A. Del , Fiebach, Maryann Z., Gulati, Anthony P., Hatton, Edward H., Houston, Kaly, Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Routy, Bertrand , Hoyo-Ulloa, Irma , Gupta, Shilpa , Sharifi, Nima , Hoppenot, Claire , Demetri, George D., Zarif, Talal El , Freeman, Dory , Nohria, Anju, Tolaney, Sara M. , Zhang, Tian , Dzimitrowicz, Hannah, Leighton, John, Lynch, Ryan C. , Portuguese, Andrew J. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Dansoa, Yvonne , Manikowski, Jesse J. , Vadakara, Joseph , Yossef, Kristena, Beckerman, Jennifer, Goyal, Sharad , Messing, Ian , Provenzano, Destie , Steffes, Dawn R., Clément, Jessica , Cosin, Jonathan A. , Daher, Ahmad , Dailey, Mark E., Hosmer, Wylie, Hsu, Emily , Jayaraj, Asha, Mather, Jeff, Menendez, Alvaro G. , Nadkarni, Rajani, Serrano, Oscar K. , Tejwani, Sheela , Accordino, Melissa , Bodin, Brianne E, Khan, Shaheer , Masson, Cynthia, Alexander, Mariam , Matar, Sara , Bernicker, Eric , Deeken, John F. , Jeffords, Kelly J., Shafer, Danielle , Cárdenas‐Delgado, Ana I., Campos, Rogelio Cuervo, Ramirez, Ana, Valdez-Reyes, Nadia Melissa, Gill, David , Lewis, Mark A. , Low, Clarke A., Rhodes, Terence D., Jones, Michelle, Mansoor, Abdul-Hai, Mashru, Sandeep H., Werner, Mica A., Cohen, Aaron , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Williamson, Staci, Lewis, Grant C., Smith, Stephanie J., Akhtari, Mojtaba, Castillo, Dan R., Cortez, Kimberly, Park, Kyu, Reeves, Mark E. , O’Connor, Timothy E. , Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Ramesh, Vidhyalakshmi , Wilson, Grace L. , Bardia, Aditya , Gainor, Justin F. , Peppercorn, Jeffrey , Reynolds, Kerry L. , Zubiri, Leyre , Campian, Jian , Riaz, Irbaz B, Williams, Colt , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Wang, Chen‐Pin , Bouganim, Nathaniel , Elkrief, Arielle , Moria, Feras, Panasci, Justin , Nanchal, Rahul , Bahadur, Nadia , Nambiar, Puja H. , Papadopoulos, Esperanza B. , Riely, Gregory J. , Rosenberg, Jonathan E., Cerrone, Kim, Dill, Jennifer A. , Faller, Bryan A. , Ajmera, Archana , Brouha, Sharon S. , Choi, Sharon , Bhatt, Padmanabh , Mariano, Melissa G., Thomson, Carey C. , Glace, Mary Grace, Knoble, Jeanna, Zacks, Rosemary, Blau, Sibel , Brown, CarrieAnn, Namburi, Swathi, Pomerantz, Lauren , Rovito, Marc A., Advani, Pragati E., Cronin, Tara, Fleissner, Bridget, Goel, Shipra , Gopalakrishnan, Dharmesh , Hernandez‐Ilizaliturri, Francisco J. , Kariapper, Ariffa, Levine, Ellis , Wicher, Camille P., Misdary, Christian, Shah, Mansi , Batist, Gerald , Cook, Erin , Esfahani, Khashayar , Ferrario, Cristiano , Lau, Susie , Ma, Kim, Rudski, Lawrence , Dutra, Míriam Santos , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Dixon, Becky, Heilman, Hannah, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Lopes, Gilberto , Cardenas, Karen de, Russell, Karen , Stith, Brittany, Taylor, Sharona, Klamerus, Justin F., Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Abbasi, Saqib Hussen, Annis, Sandy, Greenland, Steven, Jones, Regina, Kasi, Anup , Rock, Crosby D. , Wulff‐Burchfield, Elizabeth , Smits, Melissa, Weiß, Matthias , Chism, David D. , Owenby, Susie, Ang, Celina , Galsky, Matthew D. , Metzger, Megan , Uyehara, Catherine, Lashley, Latoya N., Sueyoshi, Mark, Patel, Kanishka G. , Riess, Jonathan W. , Borno, Hala T. , Rubinstein, Samuel M. , Ahmad, Syed A. , Grover, Punita , Jandarov, Roman , Kharofa, Jordan , Marcum, Michelle, Sohal, Davendra , Zamulko, Olga , Balmaceda, Nicole , Geiger, Christopher L., Russ, Atlantis Dawn, Saker, Haneen , Choi, Horyun, Feldman, Lawrence , Gantt, Gerald, Hoskins, Kent , Khan, Mahir, Liu, Li , Nguyen, Ryan H., Schwartz, Candice, Venepalli, Neeta K. , Boldt, Anne, Fecher, Leslie A. , Su, Chris, Bijjula, Ragneel R., Mavromatis, Blanche H., Seletyn, Mildred E., Wood, Barbara R., Kaklamani, Virginia , Charles, Lawrence J., Cheng, Alex , Ding, Tan , Enriquez, Kyle T. , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Lewis, Judy T., Reid, Sonya , Saif, Sara, Slosky, David, Solórzano, Carmen C. , Sun, Tianyi , Yang, Yuanchu James , Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Moore, Joan K., Cabalona, Wilhelmina D., Shisler, Elizabeth, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Castellano, Cecilia A. , Ravindranathan, Deepak , LoRusso, Patricia , Lustberg, Maryam B. , Masters, Tyler, Mishra, Sanjay , Zubiri, Leyre , Fiala, Mark A , Bilen, Mehmet A , Portuguese, Andrew J , Lustberg, Maryam , Gulati, Shuchi , Shah, Pankil , Awosika, Joy A. , Bashir, Babar , Berg, Stephanie , De‐la‐Rosa‐Martinez, Daniel , Egan, Pamela , Fein, Joshua Alexander , Friese, Christopher R. , Griffiths, Elizabeth A. , Hwang, Clara , Joshi, Monika , Labaki, Chris , Latif, Tahir , Nagaraj, Gayathri , Nakasone, Elizabeth S. , Razavi, Pedram , Ruíz‐García, Erika , Saliby, Renée Maria , Tagalakis, Vicky , Vilar‐Compte, Diana , Wise-Draper, Trisha Michel , Wotman, Michael T. , Shyr, Yu , Warner, Jeremy L. , Shah, Dimpy P. , Rosovsky, Rachel , Goel, Sanjay , Halmos, Balázs , Sica, Roberto Alejandro , Henderson, Jeffrey P. , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Thompson, Michael A. , Loree, Jonathan M. , Lam, Barbara, Peters, Mary Linton B , Farmakiotis, Dimitrios , Olszewski, Adam J. , Hatton, Edward, Rose, Suzanne J. , Nizam, Amanda , Pennell, Nathan A , Li, Ang , Bitterman, Danielle S. , Choueiri, Toni K. , Florez, Narjust , Giordano, Antonio , Morgans, Alicia K. , Nohria, Anju , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Graber, Jerome J. , Hawley, Jessica E. , Loggers, Elizabeth T , Lyman, Gary H , Su, Christopher , Tachiki, Lisa , Yeh, Albert C. , Gatson, Na Tosha , Makary, Mina S. , Rao, Yuan James , Rosenstein, Lori J. , Elias, Rawad , Eton, Omar , Yu, Peter Paul , Gadgeel, Shirish M. , Bhutani, Divaya , Hershman, Dawn L. , Ingham, Matthew , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Sachs, Zohar , Wilson, Grace, Boland, Genevieve M. , Smith, Katherine E. , Bekaii‐Saab, Tanios , Desai, Aakash , Hálfdánarson, Þorvarður R. , Joyner, Michael J. , Senefeld, Jonathon W. , Ramirez, Amelie G , Mesa, Ruben A. , Papenburg, Jesse , Vinh, Donald Cuong , Singh, Harpreet , Bao, Ting , O'Cearbhaill, Roisin E , Philip, John, Robson, Mark E. , Rosenberg, Jonathan E., Schoenfeld, Adam Jacob , Tamimi, Rulla M. , Dill, Jennifer, Hsiao, Albert , Reid, Erin G , Rink, Cameron L. , Jain, Prantesh , Moffitt, Melissa , O’Connor, Tracey L. , Puzanov, Igor , Smith, Laurie J., Zsíros, Emese , Jabbour, Salma K , Cook, Erin, Miller, Wilson H. , Wilchesky, Machelle , McNair, Christopher M. , Khaki, Ali Raza , Nagpal, Seema , Wu, Julie , Whaley, David, Gatti-Mays, Margaret Elena , Jhawar, Sachin R. , Palmer, Joshua D. , Stover, Daniel G. , Weiss, Matthias, Berenberg, Jeffrey L. , Fazio, Alyson, Huber, Kathryn E. , Small, Eric J. , Zhang, Sylvia , Andermann, Tessa M. , Jensen, Christopher Edward , Wood, William A. , Li, Ningjing , Abidi, Maheen Z. , Bowles, Daniel W. , Markham, Merry Jennifer , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H., Pasquinelli, Mary M. , Vikas, Praveen , Zakharia, Yousef , Zaman, Qamar U., Brown, Alaina J. , Crispens, Marta Ann , Croessmann, Sarah , Davis, Elizabeth J. , Ding, Tan, Duda, Stephany N. , Hausrath, Daniel J. , Li, Xuanyi , Prescott, Lauren Shore , Wang, Lucy Lu , Aboulafia, David M. , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine , Painter, Corrie , Peters, Solange

Mayo Clinic

JAMA Oncology | August 17, 2023 | Volume: 9 | Issue: 10 | Pages: 1390

10.1001/jamaoncol.2023.2934 | PMID 37589970 Get It

ImportanceSystematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking.ObjectiveTo assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer.Design, Setting, and ParticipantsThis registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022.ExposureTreatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19.Main Outcomes and MeasuresMain outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up.ResultsOf 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13).Conclusions and RelevanceIn this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19–related thromboembolism in patients with cancer.
Highlights From the Annual Meeting of the American Epilepsy Society 2022
Valencia, Ignacio , Alexander, Allyson , Andrade, Danielle M. , Arévalo, Miguel , Auer, Nancy A. , Bartoloméi, Fabrice , Becker, Danielle A. , Bernasconi, Andrea , Bernasconi, Neda , Bhatnagar, Shivani , Blumenfeld, Hal , Burdette, David E. , Conner, Kelly , Conway, Jeannine M. , Diaz-Arastia, Ramon, Drees, Cornelia , French, Jacqueline A. , Ganguly, Taneeta M. , Gotman, Jean , Guilfoyle, Shanna M., Gupta, Gita , Hentges, Katie, Huh, Linda , Kelley, Sarah A. , Vega‐Talbott, Maite La, Lam, Alice , Lowenstein, Daniel H. , Maturu, Sarita , McDonald, Carrie R. , McKee, Heather , Meador, Kimford J. , Michael, Elizabeth H., Mikati, Mohamad A. , Mitchell, James , Myers, Leah S. , Naritoku, Dean K., Neville, Kerri, Pavlova, Milena , Perry, Μ. Scott , Plueger, Madona, Pugh, Mary Jo , Quigg, Mark , Reddy, Shilpa B. , Reynolds, Tamara S. , Santana‐Gomez, Cesar , Schommer, Linsday, Shellhaas, Renée A. , Shrey, Daniel W. , Singh, Rani K. , Suleman, Saher, Templer, Jessica W. , Varadkar, Sophia , Velez‐Ruiz, Naymee , Velı́šková, Jana , Voskobiynyk, Yuliya , Wagner, Janelle L. , Wagnon, Jacy L. , Waller, Claire, Waller, Jill, Welborn, Michelle, Shellhaas, Renée A , Mikati, Mohamad A , Andrade, Danielle M , French, Jacqueline , Meador, Kimford J , Templer, Jessica W , McKee, Heather Ravvin , Ganguly, Taneeta Mindy , Burdette, David E , Valencia, Ignacio , Arevalo-Astrada, Miguel, Rubiños, Clio , Auer, Nancy, Bainbridge, Jacquelyn L. , Baxendale, Sallie , Berg, Anne T. , Bernhardt, Boris C. , Bhatnagar, Shivani, Blümcke, Ingmar , Buchanan, Gordon F. , Burneo, Jorge G. , Busch, Robyn M. , Chauvel, Patrick , Chin, Jeannie , Clifford, Lisa M. , Cook, Mark , Drees, Cornelia , Gelfand, Michael , Glauser, Tracy A. , Gleichgerrcht, Ezequiel L. , Goldman, Alica M. , González-Martínez, Jorge , Grinspan, Zachary M. , Hammer, Michael F. , Hartman, Adam L. , Hogan, R Edward , Hyslop, Ann , Jobst, Barbara C. , Josephson, Colin B. , Knupp, Kelly G. , Koepp, Matthias J. , Kothare, Sanjeev V. , Krook-Magnuson, Esther , Kwasa, Jasmine A. C. , Lee, Jong Woo , Mayor, Luis Carlos , McKhann, Guy M. , Mefford, Heather C. , Millichap, J Gordon , Noebels, Jeffrey L. , O’Brien, Terence J. , Oluigbo, Chima , Patel, Anup D. , Paz, Jeanne T. , Pennell, Page B. , Perucca, Piero , Pitkänen, Asla , Ryan, Christopher, Sajatovic, Martha , Schuele, Stephan , Sperling, Michael R. , Thom, Maria , Trinka, Eugen , Wang, Irène , Wirrell, Elaine

Mayo Clinic

Epilepsy Currents | August 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597231187227 Get It

With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.
Evidence-based clinical practice guidelines on postdural puncture headache: a consensus report from a multisociety international working group
Uppal, Vishal , Russell, Robin , Sondekoppam, Rakesh V. , Ansari, Jessica , Baber, Zafeer, Chen, Yian , DelPizzo, Kathryn , Kalagara, Hari , Kissoon, Narayan , Leffert, Lisa , Μoka, Εleni , Rodriguez, Stephen E. , Dirzu, Dan Sebastian , Kalagara, Hari , Kissoon, Narayan R , Kranz, Peter G , Leffert, Lisa , Lim, Grace , Lobo, Clara , Lucas, Dominique Nuala , Moka, Eleni , Rodriguez, Stephen E , Sehmbi, Herman , Vallejo, Manuel C , Volk, Thomas , Narouze, Samer , Uppal, Vishal , Sondekoppam, Rakesh V , Dîrzu, Dan Sebastian , Kranz, Peter G. , Lobo, Clara , Volk, Thomas , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 15, 2023 | Volume: 49 | Issue: 7 | Pages: 471-501

10.1136/rapm-2023-104817 | PMID 37582578 Get It

Introduction Postdural puncture headache (PDPH) can follow unintentional dural puncture during epidural techniques or intentional dural puncture during neuraxial procedures such as a lumbar puncture or spinal anesthesia. Evidence-based guidance on the prevention, diagnosis or management of this condition is, however, currently lacking. This multisociety guidance aims to fill this void and provide practitioners with comprehensive information and patient-centric recommendations to prevent, diagnose and manage patients with PDPH. Methods Based on input from committee members and stakeholders, the committee cochairs developed 10 review questions deemed important for the prevention, diagnosis and management of PDPH. A literature search for each question was performed in MEDLINE (Ovid) on 2 March 2022. The results from each search were imported into separate Covidence projects for deduplication and screening, followed by data extraction. Additional relevant clinical trials, systematic reviews and research studies published through March 2022 were also considered for the development of guidelines and shared with contributors. Each group submitted a structured narrative review along with recommendations graded according to the US Preventative Services Task Force grading of evidence. The interim draft was shared electronically, with each collaborator requested to vote anonymously on each recommendation using two rounds of a modified Delphi approach. Results Based on contemporary evidence and consensus, the multidisciplinary panel generated 50 recommendations to provide guidance regarding risk factors, prevention, diagnosis and management of PDPH, along with their strength and certainty of evidence. After two rounds of voting, we achieved a high level of consensus for all statements and recommendations. Several recommendations had moderate-to-low certainty of evidence. Conclusions These clinical practice guidelines for PDPH provide a framework to improve identification, evaluation and delivery of evidence-based care by physicians performing neuraxial procedures to improve the quality of care and align with patients’ interests. Uncertainty remains regarding best practice for the majority of management approaches for PDPH due to the paucity of evidence. Additionally, opportunities for future research are identified.
Consensus Practice Guidelines on Postdural Puncture Headache From a Multisociety, International Working Group
Sondekoppam, Rakesh V. , Ansari, Jessica , Baber, Zafeer, Chen, Yian, DelPizzo, Kathryn , Kalagara, Hari , Leffert, Lisa , Μoka, Εleni , Rodriguez, Stephen E. , Kalagara, Hari , Moka, Eleni , Rodriguez, Stephen E , Sondekoppam, Rakesh V , Uppal, Vishal , Russell, Robin , Chen, Yian, Dîrzu, Dan Sebastian , Kissoon, Narayan , Kranz, Peter G. , Lim, Grace , Lobo, Clara , Lucas, Dominique Nuala , Sehmbi, Herman , Vallejo, Manuel C , Volk, Thomas , Narouze, Samer

Mayo Clinic

JAMA Network Open | August 15, 2023 | Volume: 6 | Issue: 8 | Pages: e2325387

10.1001/jamanetworkopen.2023.25387 | PMID 37581893 Get It

Importance Postdural puncture headache (PDPH) can follow unintentional dural puncture during epidural techniques or intentional dural puncture during neuraxial procedures, such as a lumbar puncture or spinal anesthesia. Evidence-based guidance on the prevention, diagnosis, and management of this condition is, however, currently lacking. Objective To fill the practice guidelines void and provide comprehensive information and patient-centric recommendations for preventing, diagnosing, and managing PDPH. Evidence Review With input from committee members and stakeholders of 6 participating professional societies, 10 review questions that were deemed important for the prevention, diagnosis, and management of PDPH were developed. A literature search for each question was performed in MEDLINE on March 2, 2022. Additional relevant clinical trials, systematic reviews, and research studies published through March 2022 were also considered for practice guideline development and shared with collaborator groups. Each group submitted a structured narrative review along with recommendations that were rated according to the US Preventive Services Task Force grading of evidence. Collaborators were asked to vote anonymously on each recommendation using 2 rounds of a modified Delphi approach. Findings After 2 rounds of electronic voting by a 21-member multidisciplinary collaborator team, 47 recommendations were generated to provide guidance on the risk factors for and the prevention, diagnosis, and management of PDPH, along with ratings for the strength and certainty of evidence. A 90% to 100% consensus was obtained for almost all recommendations. Several recommendations were rated as having moderate to low certainty. Opportunities for future research were identified. Conclusions and Relevance Results of this consensus statement suggest that current approaches to the treatment and management of PDPH are not uniform due to the paucity of evidence. The practice guidelines, however, provide a framework for individual clinicians to assess PDPH risk, confirm the diagnosis, and adopt a systematic approach to its management.
Identifying Significantly Perturbed Subnetworks in Cancer Using Multiple Protein–Protein Interaction Networks
Yang, Le , Chen, Runpu , Melendy, Thomas , Goodison, Steve , Sun, Yijun

Mayo Clinic

Cancers | August 14, 2023 | Volume: 15 | Issue: 16 | Pages: 4090

10.3390/cancers15164090 | PMID 37627118 Get It

Background: The identification of cancer driver genes and key molecular pathways has been the focus of large-scale cancer genome studies. Network-based methods detect significantly perturbed subnetworks as putative cancer pathways by incorporating genomics data with the topological information of PPI networks. However, commonly used PPI networks have distinct topological structures, making the results of the same method vary widely when applied to different networks. Furthermore, emerging context-specific PPI networks often have incomplete topological structures, which pose serious challenges for existing subnetwork detection algorithms. Methods: In this paper, we propose a novel method, referred to as MultiFDRnet, to address the above issues. The basic idea is to model a set of PPI networks as a multiplex network to preserve the topological structure of individual networks, while introducing dependencies among them, and, then, to detect significantly perturbed subnetworks on the modeled multiplex network using all the structural information simultaneously. Results: To illustrate the effectiveness of the proposed approach, an extensive benchmark analysis was conducted on both simulated and real cancer data. The experimental results showed that the proposed method is able to detect significantly perturbed subnetworks jointly supported by multiple PPI networks and to identify novel modular structures in context-specific PPI networks.